ジプラシドン
ジプラシドン 物理性質
- 融点 :
- 213-215°C
- 沸点 :
- 554.8±50.0 °C(Predicted)
- 比重(密度) :
- 1.369±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- Sealed in dry,Room Temperature
- 溶解性:
- DMSO（微量）、メタノール（微量）
- 外見 :
- 個体
- 酸解離定数(Pka):
- 13.34±0.20(Predicted)
- 色:
- ブラウン～ダークブラウン
- Merck :
- 14,10171
- CAS データベース:
- 146939-27-7(CAS DataBase Reference)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-1628 |
ジプラシドン
Ziprasidone |
146939-27-7 |
250mg |
￥75000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-1628 |
ジプラシドン
Ziprasidone |
146939-27-7 |
1g |
￥175000 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML3035 |
≥97% (HPLC)
Ziprasidone hydrochloride hydrate ≥97% (HPLC) |
146939-27-7 |
10MG |
￥11800 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML3035 |
≥97% (HPLC)
Ziprasidone hydrochloride hydrate ≥97% (HPLC) |
146939-27-7 |
50MG |
￥47400 |
2024-03-01 |
購入 |
|
東京化成工業
|
Z0034 |
ジプラシドン >98.0%(HPLC)
Ziprasidone
>98.0%(HPLC) |
146939-27-7 |
100mg |
￥12100 |
2024-03-01 |
購入 |
ジプラシドン 化学特性,用途語,生産方法
外観
白色～ほとんど白色粉末～結晶
効能
統合失調症治療薬, 神経遮断薬
化学的特性
Tan Solid
使用
Labelled Ziprasidone, which is used as an antipsychotic. Combined serotonin (5HT2) and dopamine (D2) receptor antagonist.
定義
ChEBI: A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.
生物学の機能
"Ziprasidone is chemically similar to risperidone but with a substitution of piperzinyl and benzisothiazole for
piperidinyl and benzisoxazole and with minor aromatic modification. Like risperidone, ziprasidone is a high-affinity
antagonist at 5-HT2A/C and D2 receptors as well as at adrenergic α1/α2 and histamine H1 receptors. Moreover,
ziprasidone can activate 5-HT1A receptors that regulate dopaminergic neurotransmission in brain regions
involved in critical cognitive functions. Thus, in addition to D2 partial agonism, 5-HT1A agonism is now
thought to be an important pharmacological property for atypical antipsychotic drug efficacy.
一般的な説明
Ziprasidone (Geodon, a benzisothiazolpiprazinylindolonederivative) also has the structuralfeatures of a hybrid molecule between a butyrophenone antipsychoticand a trazodone-like antidepressant. It is highlymetabolized to four major metabolites, only one of which, Smethyldihydroziprasidone,likely contributes to its clinical activity. In humans, less than 5% of the dose isexcreted unchanged. Reduction by aldehyde oxidase accountsfor about 66% of ziprasidone metabolism; two oxidative pathwaysinvolving hepatic CYP3A4 account for the remainder.
作用機序
Ziprasidone
(half-life, 6 hours) has an oral bioavailability of approximately 60%, which can be enhanced in the presence of fatty
foods. It is extensively metabolized (<5% excreted unchanged) by aldehyde oxidase, which results in reductive
cleavage of the S–N bond, and then by S-methylation. Ziprasidone also can undergo CYP3A4-catalyzed
N-dealkylation and S-oxidation.
ジプラシドン 上流と下流の製品情報
原材料
準備製品
ジプラシドン 生産企業
Global( 211)Suppliers
146939-27-7(ジプラシドン)キーワード:
- 146939-27-7
- Ziprasidone
- CP-88059：CP-88059-1
- 1,2-Benzisothiazole, 3-(1-piperazinyl)-, monohydrochlorideH-indol-2-one, 6-chloro-5-(2-chloroethyl)-1,3-dihydro
- 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
- Ziprasidone HBr
- 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one
- Ziprasidone solution
- 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one
- 5-[2-[4-(1,2-Benzisothiazol-3yl)-1-piperazinyl-d8]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one
- 2H-Indol-2-one, 5-2-4-(1,2-benzisothiazol-3-yl)-1-piperazinylethyl-6-chloro-1,3-dihydro-
- ZIPRASIDONE: ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE
- CP 88059
- Hydrochloric acid(base)
- Ziprasidone for system suitability 1 CRS
- Ziprasidone for system suitability 2 CRS
- Ziprasidone Free Base
- Ziprasidone USP/EP/BP
- ZIPRASIDONE-D8
- Geodon
- ジプラシドン
- 5-{2-[4-(1,2-ベンゾチアゾール-3-イル)ピペラジン-1-イル]エチル}-6-クロロ-2,3-ジヒドロ-1H-インドール-2-オン
- 6-クロロ-5-[2-[4-(1,2-ベンゾイソチアゾール-3-イル)ピペラジン-1-イル]エチル]-1,3-ジヒドロ-2H-インドール-2-オン